Table 1.

Patient Eligibility.

Inclusion Criteria
Male or female
≥5 years of age
Presence of a symptomatic venomous snakebite
Symptom onset within 10 h of eligibility assessment
Willingness to provide informed consent prior to initiation of study procedure
Patients must meet inclusion criteria in one of two categories:
Category 1: Patient has not completed first dose of antivenom			Category 2: Patient has completed initial dose of antivenom
SSS inclusion score			SSS inclusion score
≥2 in one system and ≥1 in another system			≥2 in one system and ≥1 in another system
OR			OR
≥3 in at least one system			≥3 in at least one system
			AND
			CGI-I score ≥ 5
* Local wound, pulmonary, cardiovascular, hematologic, or nervous system scores only. GI and renal scores are not used as inclusion criteria.
Exclusion Criteria
Clinically significant upper GI bleed History of cerebral vascular accident or intracranial bleeding of any kind History of acute coronary syndrome Severe pulmonary hypertension			Known history of inherited bleeding or coagulation disorder, Chronic liver disease Chronic kidney disease On anticoagulation therapy Pregnant and/or breast-feeding Known allergy to varespladib